instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Encephalopathy'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypophysitis'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypothyroidism'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Inappropriate antidiuretic hormone secretion'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Meningitis aseptic'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Microangiopathic haemolytic anaemia'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephritis'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonitis'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Uveitis'. | Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
BACKGROUND
There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. ... | ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 33673446 | 19,761,769 | 2021-02-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
BACKGROUND
T cell-mediated eosinophilia is associated with numerous conditions-including atopic dermatitis, food allergies, and asthma-collectively known as the "atopic ... | ALBUTEROL, BUDESONIDE\FORMOTEROL, MONTELUKAST SODIUM | DrugsGivenReaction | CC BY | 33673870 | 19,120,052 | 2021-03-06 |
What was the dosage of drug 'ALBUTEROL'? | Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
BACKGROUND
T cell-mediated eosinophilia is associated with numerous conditions-including atopic dermatitis, food allergies, and asthma-collectively known as the "atopic ... | AS NEEDED | DrugDosageText | CC BY | 33673870 | 19,120,052 | 2021-03-06 |
What was the dosage of drug 'BUDESONIDE\FORMOTEROL'? | Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
BACKGROUND
T cell-mediated eosinophilia is associated with numerous conditions-including atopic dermatitis, food allergies, and asthma-collectively known as the "atopic ... | 160 (+) 4.5 MICROGRAM | DrugDosageText | CC BY | 33673870 | 19,120,052 | 2021-03-06 |
What was the dosage of drug 'MONTELUKAST SODIUM'? | Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
BACKGROUND
T cell-mediated eosinophilia is associated with numerous conditions-including atopic dermatitis, food allergies, and asthma-collectively known as the "atopic ... | 5 MILLIGRAM, DAILY (QD) | DrugDosageText | CC BY | 33673870 | 19,120,052 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Antineutrophil cytoplasmic antibody increased'. | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | AZATHIOPRINE, INFLIXIMAB, RITUXIMAB, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33676553 | 19,084,316 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exophthalmos'. | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHYLPREDNISOLONE, PREDNISOLONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHYLPREDNISOLONE, PREDNISOLONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lacrimation increased'. | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHYLPREDNISOLONE, PREDNISOLONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | AZATHIOPRINE, INFLIXIMAB, RITUXIMAB, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33676553 | 19,084,316 | 2021-03-06 |
What was the administration route of drug 'INFLIXIMAB'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33676553 | 19,046,927 | 2021-03-06 |
What was the administration route of drug 'RITUXIMAB'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | 15 MG/KG MONTHLY | DrugDosageText | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
What was the dosage of drug 'METHOTREXATE'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | 15 MG, 1/WEEK | DrugDosageText | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | 1 G/DAY PULSED METHYLPREDNISOLONE FOR 3 DAYS, THEN 1 MG/KG/DAY FOR FURTHER 10 DAYS | DrugDosageText | CC BY | 33676553 | 19,475,619 | 2021-03-06 |
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | UNK?10 YEARS | DrugDosageText | CC BY | 33676553 | 19,084,316 | 2021-03-06 |
What was the outcome of reaction 'Disease progression'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | Recovering | ReactionOutcome | CC BY | 33676553 | 19,046,927 | 2021-03-06 |
What was the outcome of reaction 'Granulomatosis with polyangiitis'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | Recovering | ReactionOutcome | CC BY | 33676553 | 19,046,927 | 2021-03-06 |
What was the outcome of reaction 'Orbital granuloma'? | Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis.
BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small and medium vessel vasculitis. The use of biological therapies such as rituximab and in... | Recovering | ReactionOutcome | CC BY | 33676553 | 19,046,927 | 2021-03-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | ANAKINRA, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETOPOSIDE, IMMUNE GLOBULIN NOS, PREDNISONE, RITUXIMAB, SILTUXIMAB, SIROLIMUS, THALIDOMIDE, TOCILIZUMAB | DrugsGivenReaction | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
What was the dosage of drug 'ANAKINRA'? | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | 100 MG/DIE | DrugDosageText | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
What was the dosage of drug 'ETOPOSIDE'? | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | 150 MILLIGRAM/SQ. METER, QW | DrugDosageText | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
What was the dosage of drug 'IMMUNE GLOBULIN NOS'? | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | 25 G/DIE | DrugDosageText | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
What was the dosage of drug 'RITUXIMAB'? | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | 375 MG/MQ FOUR CYCLES, CYCLICAL | DrugDosageText | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
What was the dosage of drug 'TOCILIZUMAB'? | Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
BACKGROUND
Human herpervirus-8/human immunodeficiency virus negative Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disorder sustained by a pro-inflammatory condition of hypercytokine... | 8 MILLIGRAM/KILOGRAM, BIWEEKLY | DrugDosageText | CC BY | 33676575 | 19,554,682 | 2021-03-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Constipation'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,043,265 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,043,265 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug intolerance'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE, LENALIDOMIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,093,532 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Inappropriate antidiuretic hormone secretion'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neurotoxicity'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | BORTEZOMIB, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
What was the dosage of drug 'BORTEZOMIB'? | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | UNKNOWN | DrugDosageText | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
What was the outcome of reaction 'Hyponatraemia'? | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | Recovered | ReactionOutcome | CC BY-NC-SA | 33677871 | 19,093,532 | 2021-01-14 |
What was the outcome of reaction 'Inappropriate antidiuretic hormone secretion'? | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | Recovered | ReactionOutcome | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
What was the outcome of reaction 'Neurotoxicity'? | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | Recovered | ReactionOutcome | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
What was the outcome of reaction 'Pyrexia'? | Central nervous system toxicity caused by bortezomib: five case reports and a review of literature.
Objective: To investigate the clinical features, diagnosis, and treatment of the central nervous system (CNS) toxicity caused by bortezomib. Methods: This study reports five new cases of CNS toxicity caused by bortezomib... | Recovered | ReactionOutcome | CC BY-NC-SA | 33677871 | 19,207,262 | 2021-01-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | INFLIXIMAB, MERCAPTOPURINE | DrugsGivenReaction | CC BY-NC-ND | 33678739 | 19,105,218 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | ACETAMINOPHEN, CLOSTRIDIUM BUTYRICUM SPORES STRAIN M-55, FEXOFENADINE HYDROCHLORIDE, INFLIXIMAB, MERCAPTOPURINE, MESALAMINE | DrugsGivenReaction | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What is the weight of the patient? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | 49 kg. | Weight | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'ACETAMINOPHEN'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'CLOSTRIDIUM BUTYRICUM SPORES STRAIN M-55'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'FEXOFENADINE HYDROCHLORIDE'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'INFLIXIMAB'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'MERCAPTOPURINE'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the administration route of drug 'MESALAMINE'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
What was the dosage of drug 'MERCAPTOPURINE'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | 30 MG | DrugDosageText | CC BY-NC-ND | 33678739 | 19,105,218 | 2021-08-15 |
What was the outcome of reaction 'Cerebral venous sinus thrombosis'? | High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature.
A 28-year-old woman experienced severe headache and right homonymous hemianopia after receiving high-dose infliximab for Crohn's disease. Computed tomography showed hemorrhagic infarction in the left temporal a... | Recovered with sequelae (consequent health issues) | ReactionOutcome | CC BY-NC-ND | 33678739 | 14,020,335 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases.
Pyogenic granuloma (PG) is a granulomatous elevated lesion that occurs on the skin and mucous membranes. We herein report two cases of intra-oral PG that developed during the administration of ramucirumab for gastric cancer. Case 1 involved a 55-year-o... | CAPECITABINE, CISPLATIN, PACLITAXEL, RAMUCIRUMAB, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33678742 | 19,848,131 | 2021-08-15 |
What was the dosage of drug 'CAPECITABINE'? | Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases.
Pyogenic granuloma (PG) is a granulomatous elevated lesion that occurs on the skin and mucous membranes. We herein report two cases of intra-oral PG that developed during the administration of ramucirumab for gastric cancer. Case 1 involved a 55-year-o... | XELOX REGIMEN | DrugDosageText | CC BY-NC-ND | 33678742 | 19,848,146 | 2021-08-15 |
What was the dosage of drug 'PACLITAXEL'? | Ramucirumab-related Oral Pyogenic Granuloma: A Report of Two Cases.
Pyogenic granuloma (PG) is a granulomatous elevated lesion that occurs on the skin and mucous membranes. We herein report two cases of intra-oral PG that developed during the administration of ramucirumab for gastric cancer. Case 1 involved a 55-year-o... | WEEKLY | DrugDosageText | CC BY-NC-ND | 33678742 | 19,848,131 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myokymia'. | Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
We herein report a 48-year-old woman receiving eribulin mesylate for breast cancer who presented with gait disorder, distal limb paresthesia, and weakness progressing monthly. A nerve conduction study indicated demye... | ERIBULIN | DrugsGivenReaction | CC BY-NC-ND | 33678744 | 19,840,712 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nerve conduction studies abnormal'. | Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
We herein report a 48-year-old woman receiving eribulin mesylate for breast cancer who presented with gait disorder, distal limb paresthesia, and weakness progressing monthly. A nerve conduction study indicated demye... | ERIBULIN | DrugsGivenReaction | CC BY-NC-ND | 33678744 | 19,840,712 | 2021-08-15 |
What was the administration route of drug 'ERIBULIN'? | Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
We herein report a 48-year-old woman receiving eribulin mesylate for breast cancer who presented with gait disorder, distal limb paresthesia, and weakness progressing monthly. A nerve conduction study indicated demye... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 33678744 | 19,840,712 | 2021-08-15 |
What was the outcome of reaction 'Myokymia'? | Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
We herein report a 48-year-old woman receiving eribulin mesylate for breast cancer who presented with gait disorder, distal limb paresthesia, and weakness progressing monthly. A nerve conduction study indicated demye... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678744 | 19,840,712 | 2021-08-15 |
What was the outcome of reaction 'Nerve conduction studies abnormal'? | Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
We herein report a 48-year-old woman receiving eribulin mesylate for breast cancer who presented with gait disorder, distal limb paresthesia, and weakness progressing monthly. A nerve conduction study indicated demye... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678744 | 19,840,712 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | METHOTREXATE, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 33678748 | 19,144,983 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | AZATHIOPRINE, METHOTREXATE, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 33678748 | 19,166,897 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | HUMAN IMMUNOGLOBULIN G, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC-ND | 33678748 | 19,071,211 | 2021-08-15 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33678748 | 19,071,211 | 2021-08-15 |
What was the administration route of drug 'PREDNISOLONE'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678748 | 19,091,993 | 2021-08-15 |
What was the administration route of drug 'TACROLIMUS'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33678748 | 19,091,993 | 2021-08-15 |
What was the outcome of reaction 'Condition aggravated'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678748 | 19,144,983 | 2021-08-15 |
What was the outcome of reaction 'Dermatomyositis'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678748 | 19,166,897 | 2021-08-15 |
What was the outcome of reaction 'Panniculitis'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678748 | 19,166,897 | 2021-08-15 |
What was the outcome of reaction 'Rebound effect'? | Painless Panniculitis upon the Treatment of Clinically Amyopathic Dermatomyositis with Anti-MDA5 Antibody.
Panniculitis, a rare cutaneous manifestation in patients with dermatomyositis (DM), usually presents as a painful erythematous lesion. We herein report a 32-year-old woman with panniculitis that appeared as an ind... | Recovering | ReactionOutcome | CC BY-NC-ND | 33678748 | 19,166,897 | 2021-08-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic haematoma'. | Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a set of heterogenous disorders of thrombotic microangiopathy defined by thrombocytopenia, hemolytic anemia, and acute renal failure that is not mediated ... | LISINOPRIL, PHYTONADIONE, WARFARIN | DrugsGivenReaction | CC BY-NC-ND | 33678802 | 19,694,327 | 2021-03-08 |
What was the administration route of drug 'PHYTONADIONE'? | Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a set of heterogenous disorders of thrombotic microangiopathy defined by thrombocytopenia, hemolytic anemia, and acute renal failure that is not mediated ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33678802 | 19,694,327 | 2021-03-08 |
What was the dosage of drug 'COAGULATION FACTOR IX HUMAN\COAGULATION FACTOR VII HUMAN\COAGULATION FACTOR X HUMAN\PROTHROMBIN'? | Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a set of heterogenous disorders of thrombotic microangiopathy defined by thrombocytopenia, hemolytic anemia, and acute renal failure that is not mediated ... | 100 INTERNATIONAL UNIT/KILOGRAM | DrugDosageText | CC BY-NC-ND | 33678802 | 19,047,900 | 2021-03-08 |
What was the dosage of drug 'PHYTONADIONE'? | Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a set of heterogenous disorders of thrombotic microangiopathy defined by thrombocytopenia, hemolytic anemia, and acute renal failure that is not mediated ... | 5 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33678802 | 19,694,327 | 2021-03-08 |
What was the outcome of reaction 'Atypical haemolytic uraemic syndrome'? | Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is a set of heterogenous disorders of thrombotic microangiopathy defined by thrombocytopenia, hemolytic anemia, and acute renal failure that is not mediated ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33678802 | 19,061,907 | 2021-03-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular tachycardia'. | Overdrive suppression of postoperative sustained ventricular tachycardia by atrial pacing and its hemodynamic effect.
Sustained ventricular tachycardia (VT) in the early postoperative period following intracardiac repair for tetralogy of Fallot is rare. In stable VT, amiodarone forms the mainstay of management. However... | EPINEPHRINE, MILRINONE, NOREPINEPHRINE | DrugsGivenReaction | CC BY-NC-SA | 33679069 | 20,041,968 | 2021 |
What was the dosage of drug 'MILRINONE'? | Overdrive suppression of postoperative sustained ventricular tachycardia by atrial pacing and its hemodynamic effect.
Sustained ventricular tachycardia (VT) in the early postoperative period following intracardiac repair for tetralogy of Fallot is rare. In stable VT, amiodarone forms the mainstay of management. However... | UNK (0.05 MIC/KG/MIN) | DrugDosageText | CC BY-NC-SA | 33679069 | 20,041,968 | 2021 |
What was the outcome of reaction 'Ventricular tachycardia'? | Overdrive suppression of postoperative sustained ventricular tachycardia by atrial pacing and its hemodynamic effect.
Sustained ventricular tachycardia (VT) in the early postoperative period following intracardiac repair for tetralogy of Fallot is rare. In stable VT, amiodarone forms the mainstay of management. However... | Recovering | ReactionOutcome | CC BY-NC-SA | 33679069 | 20,041,968 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypogammaglobulinaemia'. | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33679772 | 19,286,872 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33679772 | 19,286,872 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 33679772 | 19,286,872 | 2021 |
What was the administration route of drug 'PREDNISONE'? | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | Oral | DrugAdministrationRoute | CC BY | 33679772 | 19,286,872 | 2021 |
What was the dosage of drug 'HYDROXYCHLOROQUINE'? | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | UNKNOWN | DrugDosageText | CC BY | 33679772 | 19,286,872 | 2021 |
What was the dosage of drug 'PREDNISONE'? | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | UNKNOWN | DrugDosageText | CC BY | 33679772 | 19,286,872 | 2021 |
What was the outcome of reaction 'Neutropenia'? | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | Recovered | ReactionOutcome | CC BY | 33679772 | 19,286,872 | 2021 |
What was the outcome of reaction 'Pyrexia'? | Case Report: A Novel TNFAIP3 Mutation Causing Haploinsufficiency of A20 With a Lupus-Like Phenotype.
Genetic mutations that result in loss-of-function of the protein A20 result in an early-onset autoinflammatory disease-haploinsufficiency of A20 (HA20). The reported clinical presentations of HA20 include a Behcet's dis... | Recovered | ReactionOutcome | CC BY | 33679772 | 19,286,872 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal sepsis'. | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | DOCETAXEL, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY | 33680082 | 19,659,872 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric perforation'. | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | DOCETAXEL, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY | 33680082 | 19,659,874 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | DOCETAXEL, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY | 33680082 | 19,659,874 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary sepsis'. | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | DOCETAXEL, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY | 33680082 | 19,657,696 | 2021 |
What was the administration route of drug 'DOCETAXEL'? | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33680082 | 19,659,874 | 2021 |
What was the administration route of drug 'FLUOROURACIL'? | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33680082 | 19,659,874 | 2021 |
What was the administration route of drug 'LEUCOVORIN CALCIUM'? | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33680082 | 19,659,874 | 2021 |
What was the administration route of drug 'OXALIPLATIN'? | Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Gastric cancer is the fifth cause of cancer incidence worldwide. Multidisciplinary approaches that improve the survival are need... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33680082 | 19,659,874 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report.
Capicua transcriptional repressor (CIC)-rearranged sarcoma is an Ewing-like sarcoma with an aggressive clinical course and poor prognosis. No standard treatment has been established. The present study describes a case... | CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, ETOPOSIDE, IFOSFAMIDE, TRABECTEDIN, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 33680459 | 19,217,525 | 2021-04 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.